Abstract #4203
Pharmacological MRI with T1 Contrast Agents
Richard Baheza 1 , Nellie Byun 2 , Adam Stark 3 , and John C. Gore 3,4
1
RADIOLOGY AND RADIOLOGICAL SCIENCES,
Vanderbilt University Medical Center, NASHVILLE, TN,
United States,
2
PHARMACOLOGY,
Vanderbilt University Medical Center, NASHVILLE, TN,
United States,
3
VANDERBILT
UNIVERSITY INSTITUTE OF IMAGING SCIENCE, Nashville, TN,
United States,
4
BIOMEDICAL
ENGINEERING, Vanderbilt University, Nashville, TN,
United States
We performed whole brain pharmacological MRI (phMRI) at
9.4T with the FDA approved T1 contrast agent Magnevist
using an optimized 3D acquisition sequence to detect
amphetamine-induced brain activity in rats. Increasing
the psychostimulant dose from 2.0 to 4.0 mg/kg elevated
the acquired signal increases from 1.870.55% to
4.710.33% in the caudate-putamen, demonstrating that
the method is sensitive to drug concentration. These
data validate the utility of using a T1 shortening agent
with 3D acquisition for phMRI. This method has
translational potential to clinical drug studies using
FDA-approved contrast agents.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
